Ther­alase iden­ti­fies “su­per­po­tent anti-can­cer drugs”

Ther­alase Tech­nolo­gies Inc. has iden­ti­fied a new plat­form of “su­per­po­tent anti-can­cer drugs.” The PDCs are ap­par­ently 10 bil­lion times more po­tent in killing can­cer cells than other tested PDCs.

Stockwatch Daily - - FRONT PAGE - Mr. Roger Du­moulin-White re­ports

THER­ALASE TECH­NOLO­GIES Inc. has re­cently iden­ti­fied a new plat­form of su­per­po­tent anti-can­cer drugs, or PDCs, dis­cov­ered by Dr. Sherri McFar­land, PhD, pro­fes­sor, depart­ment of chem­istry and bio­chem­istry, Univer­sity of North Carolina at Greens­boro, the orig­i­nal in­ven­tor of the Ther­alase li­censed ruthe­nium-based PDCs.

Dr. McFar­land has dis­cov­ered a new gen­er­a­tion of PDCs, that are 10 bil­lion times more po­tent in killing can­cer cells than other tested PDCs. It only takes a few mol­e­cules of the new PDCs to kill can­cer cells, in vitro, when ac­ti­vated by vis­i­ble light.

The new PDCs also ex­hibit very low, in vitro, dark cy­to­tox­i­c­ity (can­cer cell kill in the ab­sence of light), pro­vid­ing a very low tox­i­c­ity to cells.

This pho­to­cy­to­tox­i­c­ity (can­cer cell kill in the pres­ence of light) ac­tiv­ity has been op­ti­mized, with­out in­creas­ing the dark cy­to­tox­i­c­ity.

These next-gen­er­a­tion PDCs are thus able to in­crease in vitro ther­a­peu­tic mar­gins (abil­ity to kill can­cer cells when light ac­ti­vated ver­sus when not light ac­ti­vated) by 10 or­ders of mag­ni­tude over tested PDCs and were con­ceived by Dr. McFar­land by de­sign­ing the most po­tent PDCs for sys­temic (in­tra­venous or IV) pa­tient ad­min­is­tra­tion at the low­est pos­si­ble dose.

The pre­lim­i­nary data, ob­tained to date, demon­strate that the new PDCs ex­hibit pref­er­en­tial prop­er­ties for IV de­liv­ery and are thus able to greatly ex­pand the scope of can­cers that can be tar­geted by this new plat­form PDT tech­nol­ogy.

Dr. McFar­land stated that: “I am de­lighted that we have dis­cov­ered new PDCs that are able to in­crease the pho­to­dy­namic ther­apy (PDT) po­tency over other tested PDCs by 10 or­ders of mag­ni­tude (10 bil­lion times), us­ing highly spe­cial­ized method­olo­gies and for­mu­la­tions. The very large and un­prece­dented ther­a­peu­tic mar­gins make safe, IV sys­temic de­liv­ery of these new PDCs that much more pos­si­ble, vastly in­creas­ing the num­ber of can­cers that can be tar­geted with this

PDT tech­nol­ogy. With our PDC TLD-1433 show­ing prom­ise in a phase Ib clin­i­cal trial for treat­ing non-mus­cle in­va­sive blad­der can­cer (NMIBC) with PDT, it is an ex­cit­ing time to be work­ing closely with the Ther­alase team on the de­vel­op­ment of the next-gen­er­a­tion PDCs for hard-to-treat can­cers such as glioblas­toma mul­ti­forme (GBM), a deadly form of brain can­cer.”

Dr. Arkady Man­del, MD, PhD, DSc, chief sci­en­tific of­fi­cer of Ther­alase, stated that: “The abil­ity to in­crease the light tox­i­c­ity of the PDC by 10 or­ders of mag­ni­tude with­out af­fect­ing the dark tox­i­c­ity of the PDC, is a dra­matic dis­cov­ery. The in vitro re­sults pre­sented by Dr. McFar­land opens up a tremen­dous op­por­tu­nity to de­velop and clin­i­cally eval­u­ate a new PDT tech­nol­ogy plat­form that may mit­i­gate the risk of sys­temic tox­i­c­ity, while of­fer­ing an ex­cep­tional po­tency in the de­struc­tion of can­cer cells; hence, safely and ef­fec­tively, de­stroy­ing a greater quan­tity of can­cer cells per sin­gle treat­ment. This pro­vides the com­pany with an op­por­tu­nity to estab­lish a new realm in the types of can­cers that can safely and ef­fec­tively be treated with this cut­ting-edge PDT tech­nol­ogy.”

Roger Du­moulin-White, PEng, pres­i­dent and chief ex­ec­u­tive of­fi­cer of Ther­alase, stated that: “Ther­alase, in its col­lab­o­ra­tive re­search part­ner­ship with Dr. McFar­land, con­tin­ues to push the en­ve­lope on what these PDCs are ca­pa­ble of in the de­struc­tion of can­cer cells. I look for­ward to scal­ing up the man­u­fac­ture of these new PDCs to al­low use in a new phase Ib clin­i­cal study.”

About Ther­alase Tech­nolo­gies Inc.

Ther­alase Tech­nolo­gies in its ther­a­peu­tic laser tech­nol­ogy (TLT) di­vi­sion de­signs, man­u­fac­tures, mar­kets and dis­trib­utes patented su­per-pulsed laser tech­nol­ogy in­di­cated for the treat­ment of chronic knee pain, and in off-la­bel use, the elim­i­na­tion of pain, re­duc­tion of in­flam­ma­tion and dra­matic ac­cel­er­a­tion of tis­sue heal­ing for nu­mer ous nerve, mus cle an d joint con­di­tions. Ther­alase’s pho­to­dy­namic ther­apy (PDT) di­vi­sion re­searches and de­vel­ops spe­cially de­signed mol­e­cules called pho­to­dy­namic com­pounds (PDCs), which have demon­strated an abil­ity to lo­cal­ize to can­cer cells and then when laser light ac­ti­vated, ef­fec­tively de­stroy them.

We seek Safe Har­bor.

Guy John An­der­son, Ran­dall Bruder, Roger John Du­moulin-White, Matthew Thomas Per­ra­ton

(TLT) Shares: 126,481,526

Newspapers in English

Newspapers from Canada

© PressReader. All rights reserved.